Residency · Residency · Oral Maxillofacial Surgery

Perioperative Management of Anticoagulant and Antiplatelet Therapy

Introduction

An increasing number of OMFS patients present on anticoagulant or antiplatelet medications for cardiovascular, cerebrovascular, or thromboembolic conditions. The perioperative decision to continue, modify, or discontinue these medications requires careful risk-benefit analysis, balancing the risk of surgical hemorrhage against the potentially life-threatening risk of thromboembolic events.

Physiology of Hemostasis

Primary hemostasis involves platelet adhesion, activation, and aggregation forming a platelet plug. Secondary hemostasis involves the coagulation cascade (intrinsic, extrinsic, and common pathways) generating a fibrin mesh. Fibrinolysis is the plasmin-mediated dissolution of the fibrin clot. Surgical hemostasis depends on intact function of all three components. Most dentoalveolar procedures involve limited surgical fields where local hemostatic measures are highly effective.

Antiplatelet Agents

Aspirin

Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), blocking thromboxane A2 production. Its platelet effect lasts the lifespan of the platelet (7-10 days). Low-dose aspirin (81 mg) for cardiovascular prophylaxis should generally not be discontinued for dentoalveolar surgery, as the risk of thrombotic events from discontinuation outweighs the bleeding risk for most OMFS procedures.

P2Y12 Receptor Inhibitors

Clopidogrel (Plavix) is an irreversible ADP receptor antagonist with a 5 to 7 day offset. Prasugrel (Effient) is more potent and irreversible with a 7 to 10 day offset. Ticagrelor (Brilinta) is reversible with a 3 to 5 day offset. These agents are commonly prescribed as dual antiplatelet therapy (DAPT) with aspirin after coronary stent placement. DAPT should never be discontinued within the critical window (6-12 months after drug-eluting stent) without cardiology consultation, as the risk of stent thrombosis carries up to 30% mortality.

Anticoagulant Agents

Warfarin (Coumadin)

Warfarin is a vitamin K antagonist that inhibits synthesis of factors II, VII, IX, and X. It is monitored by the INR (International Normalized Ratio). For most dentoalveolar procedures, warfarin is continued if the INR is 3.0 to 3.5 or less. If the INR is supratherapeutic, elective surgery is postponed and the patient referred to the prescribing physician. Reversal options include vitamin K (phytonadione) for non-urgent reversal and fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC) for urgent reversal.

Direct Oral Anticoagulants (DOACs)

Dabigatran (Pradaxa) is a direct thrombin inhibitor with idarucizumab (Praxbind) as its reversal agent. Rivaroxaban (Xarelto) is a factor Xa inhibitor with a half-life of 5 to 13 hours. Apixaban (Eliquis) is a factor Xa inhibitor with a half-life of 8 to 15 hours. Edoxaban (Savaysa) is also a factor Xa inhibitor. Factor Xa inhibitors can be reversed with andexanet alfa (Andexxa) in life-threatening bleeding. For minor dentoalveolar procedures, skipping the morning dose on the day of surgery may be considered. For major OMFS procedures, discontinuation 24 to 48 hours preoperatively is guided by renal function and agent half-life.

Heparin

Unfractionated heparin (UFH) has a short half-life (60-90 minutes), is monitored by aPTT, and is reversed with protamine sulfate. Low-molecular-weight heparin (LMWH), such as enoxaparin (Lovenox), has a longer half-life and is partially reversed by protamine. Heparin is used for bridging therapy in high-risk patients when warfarin is held.

Risk Stratification

Thrombotic Risk Assessment

High-risk conditions include mechanical mitral valve, recent stroke or TIA (within 3 months), recent VTE, and DAPT within the critical window after coronary stent placement. Moderate-risk conditions include bioprosthetic valve, atrial fibrillation with CHA2DS2-VASc score of 5 to 6, and VTE within 3 to 12 months. Low-risk conditions include atrial fibrillation with CHA2DS2-VASc score of 4 or less and VTE greater than 12 months ago.

Bleeding Risk Assessment

Low bleeding risk procedures include simple extractions, single implant placement, and biopsies. Moderate bleeding risk procedures include multiple extractions, minor bone surgery, and implant placement with grafting. High bleeding risk procedures include orthognathic surgery, fracture repair, ablative surgery, and extensive flap procedures.

Management Strategies by Procedure

Minor Dentoalveolar Surgery

Aspirin, clopidogrel, warfarin (INR 3.5 or less), and DOACs are continued in most cases. Local hemostatic measures are relied upon, including absorbable gelatin sponge, oxidized cellulose, tranexamic acid mouthwash, suturing, and compression. Tranexamic acid 5% mouthwash (swish and spit 4 times daily for 5-7 days) significantly reduces postoperative bleeding.

Major OMFS Procedures

Multidisciplinary discussion with the cardiologist or hematologist is essential. DOACs may be held 24 to 48 hours preoperatively. Warfarin bridging with LMWH may be indicated for high thrombotic risk patients. Aspirin is generally continued, while P2Y12 inhibitors may be held 5 to 7 days with cardiology approval. Availability of blood products and reversal agents is ensured.

Local Hemostatic Measures

Absorbable gelatin sponge (Gelfoam) is packed into extraction sockets. Oxidized regenerated cellulose (Surgicel) promotes platelet aggregation. Microfibrillar collagen (Avitene) serves as a hemostatic wound dressing. Tranexamic acid is available topically (mouthwash) or systemically and inhibits fibrinolysis. Bone wax controls bleeding from bony surfaces. Electrocautery (bipolar preferred in anticoagulated patients) provides soft tissue hemostasis. Primary closure through suturing reduces bleeding surface area.

Postoperative Considerations

Clear written instructions regarding bleeding management are provided. NSAIDs are avoided in patients on anticoagulants when possible due to increased bleeding risk. Follow-up is scheduled within 24 to 48 hours for patients at elevated bleeding risk. If significant postoperative hemorrhage occurs, pressure and local hemostatic agents are applied, coagulation studies are checked, and reversal is considered if bleeding is life-threatening.

Clinical Pearls

The default for most dentoalveolar procedures is to continue anticoagulant and antiplatelet therapy and manage bleeding locally. DAPT should never be discontinued without cardiology consultation, as stent thrombosis carries up to 30% mortality. Tranexamic acid mouthwash is a simple, effective adjunct for anticoagulated patients undergoing oral surgery. A same-day INR should be checked for all warfarin patients before surgery, proceeding if the INR is 3.5 or less. For major OMFS procedures, the prescribing physician should be involved early in the planning process.

References

1. Nathwani S, Wanis C. "Management of Anticoagulant and Antiplatelet Therapy in Oral Surgery." Oral Surgery. 2021;14(2):120-130.
2. Douketis JD, et al. "Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline." Chest. 2022;162(5):e545-e588.
3. Aframian DJ, Lalla RV, Peterson DE. "Management of Dental Patients Taking Common Hemostasis-Altering Medications." Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2007;103(Suppl):S45.e1-11.
4. Shi Q, et al. "Perioperative Management of Patients on Direct Oral Anticoagulants Undergoing Oral Surgery." British Journal of Oral and Maxillofacial Surgery. 2021;59(4):e84-e91.

Read this lecture as Markdown